{
    "clinical_study": {
        "@rank": "102399", 
        "arm_group": [
            {
                "arm_group_label": "Anacetrapib", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive 100-mg anacetrapib, orally, once-daily for 24 weeks. Participants will continue on once-daily 100-mg anacetrapib during 28 week open-label extension."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants will receive placebo tablet, orally, once daily for 24 weeks. Participants will be switched to once-daily 100-mg anacetrapib during 28 week open-label extension."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the effects of anacetrapib (MK-0859) on low-density\n      lipoprotein-cholesterol (LDL-C) when compared to placebo in Japanese participants with\n      dyslipidemia when added to an existing statin-modifying therapy."
        }, 
        "brief_title": "A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Dyslipidemia", 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  If female, cannot be of reproductive potential\n\n          -  Treatment with an appropriate, stable dose of statin \u00b1 other lipid modifying therapy\n             for at least 6 weeks  and who is not at LDL-C goal per their category in the Japan\n             Atherosclerosis Society guidelines\n\n        Exclusion Criteria:\n\n          -  Previously participated in a study with a cholesteryl ester transfer protein (CETP)\n             inhibitor\n\n          -  Homozygous and heterozygous familial hypercholesterolemia\n\n          -  Severe chronic heart failure\n\n          -  Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary\n             intervention (PCI), coronary artery by-pass graft (CABG), unstable angina, or stroke\n             within 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01760460", 
            "org_study_id": "0859-051", 
            "secondary_id": "132236"
        }, 
        "intervention": [
            {
                "arm_group_label": "Anacetrapib", 
                "intervention_name": "Anacetrapib", 
                "intervention_type": "Drug", 
                "other_name": "MK-0859"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo for anacetrapib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oxazolidinones"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 11, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percent Change from Baseline in LDL-C (beta-quantification [BQ] method)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percentage of Participants who Experience at Least One Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "64 weeks"
            }
        ], 
        "removed_countries": {
            "country": [
                "Japan", 
                "Taiwan"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01760460"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percent Change from Baseline in High-density Lipoprotein-cholesterol (HDL-C)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percent Change from Baseline in Non-HDL-C", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percent Change from Baseline in Apolipoprotein B (Apo-B)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percent Change from Baseline in Apolipoprotein A-I (Apo-A-I)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percent Change from Baseline in Lipoprotein(a) (Lp[a])", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}